Arformoterol

Arformoterol
	File:Arformoterol.svg
Systematic (IUPAC) name
	N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl) propan-2-yl]amino]ethyl] phenyl]formamide
Clinical data
[[Regulation of therapeutic goods \|Template:Engvar data]]	US FDA: Arformoterol;
Pregnancy; category	US: C (Risk not ruled out) ; ;
Routes of; administration	nebuliser
Legal status
Legal status	US: ℞-only ;
Pharmacokinetic data
Protein binding	52–65%
Biological half-life	26 hours
Identifiers
CAS Number	67346-49-0
ATC code	none
DrugBank	DB01274
Chemical data
Formula	C19H24N2O4
Molar mass	344.405 g/mol[[Script error: No such module "String".]]

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Arformoterol is a long acting beta-adrenoceptor agonist drug indicated for the treatment of chronic obstructive pulmonary disease (COPD). It is sold by Sepracor, under the trade name Brovana, as a solution of arformoterol tartrate to be administered twice daily (morning and evening) by nebulization.^[1]

It is the active (R,R)-enantiomer of formoterol and was approved by the United States Food and Drug Administration (FDA) on October 6, 2006 for the treatment of COPD.

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

45px	This drug article relating to the respiratory system is a stub. You can help ssf by expanding it. v d e